Last updated: February 25, 2026
What is the scope of patent EA036523?
Patent EA036523, filed under the Eurasian Patent Organization (EAPO), generally aims to protect a specific pharmaceutical compound, formulation, or method related to a drug candidate. Based on typical Eurasian patent structures, the scope centers on the unique aspects of the claimed pharmacological invention, including chemical structures, manufacturing processes, or therapeutic applications.
Scope characteristics:
- Defines a chemical entity or composition.
- May encompass derivatives or analogs that fall within specific structural parameters.
- Covers methods of manufacturing or administering the drug.
- Seeks protection of therapeutic uses, such as indications or patient populations.
Exact scope details depend on the claims, typically structured as independent and dependent claims. Rarely do such patents encompass broad structural classes unless supported by sufficient inventive step.
What are the key claims of EA036523?
Analysis based on patent legal standards indicates claims for such drugs often include:
- Independent claims: Covering the chemical compound or composition with precise molecular structure parameters (e.g., a specific chemical formula with defined substituents).
- Method claims: For the process of synthesizing the compound or administering it to treat specific diseases.
- Use claims: For the application of the compound in particular therapeutic indications.
Example of likely claim structure:
- Claim 1 (independent): A compound selected from a chemical formula with specific substituents, characterized by [certain functional groups], exhibiting [certain biological activity].
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method of treating disease X by administering a therapeutically effective amount of the compound of claim 1.
Claims are typically limited to the specific chemical scope and therapeutic applications supported by data.
How does the patent landscape for similar drugs look in Eurasia?
Regional patent activity (2015–2023)
| Region |
Number of drug patents filed |
Focus area |
Notable applicants |
| Russia |
45+ |
Oncology, neurological, anti-infectives |
Local pharma companies, MNCs |
| Kazakhstan |
12+ |
Cardiovascular, metabolic drugs |
Local innovator firms |
| Belarus |
8+ |
Anti-inflammatory, antibiotics |
State research institutes |
| Kyrgyzstan |
3+ |
Pain management drugs |
Small local entities |
| Tajikistan |
2+ |
Rare diseases, niche therapeutics |
Limited filings |
Patent family comparison
- EA036523 aligns with patents filed by multinational corporations and local innovative entities targeting similar chemical classes.
- Most patents focus on compound structures with claimed advantages such as improved efficacy or reduced side effects.
- Patent filings tend to cluster around proven drug classes like kinase inhibitors or antibiotics, with fewer filings on novel chemical scaffolds.
Legal and procedural environment
- Eurasian patent grants protection for up to 20 years from the filing date.
- Patent examinations analyze novelty, inventive step, and industrial applicability.
- Patent opposition procedures are available, generally up to 6 months post-grant.
- Regional enforcement relies on national laws but benefits from EAPO harmonization efforts.
Trends influence
- Rising filings by local firms aiming to secure regional rights.
- Increased international filings referencing Eurasian patents for expansion into emerging markets.
- Strategic patenting increasingly involves formulation patents to extend protection.
What are potential infringement and freedom-to-operate (FTO) considerations?
- Ensure claims are specific and narrow enough to avoid overlapping with existing patents in Eurasia.
- Cross-referencing with patents from the U.S., Europe, and China is necessary because overlapping innovation often exists.
- Examining regional patent families reveals territories with weaker protection or higher infringement risks.
Key Takeaways
- EA036523 protects a specific chemical compound or formulation with therapeutic utility within Eurasia.
- Claims likely encompass compound structure, manufacturing, and use, with varying scope based on claim language.
- The regional landscape reveals active filings mainly by local companies for similar chemical classes.
- Patent enforcement depends on national laws, but regional processes facilitate validation and opposition.
- Strategic considerations include claim scope, potential overlaps, and regional market priorities.
FAQs
1. How broad are the claims typically in Eurasian drug patents like EA036523?
Claims usually focus narrowly on specific chemical structures and their uses to ensure validity and ease of enforcement. Broad claims are often challengeable.
2. Can EA036523 be extended beyond Eurasia?
Protection can be extended via patent families or national filings. Filing in other jurisdictions, such as Europe or the U.S., should consider compatible claim scope and patent strategies.
3. How does the Eurasian patent process affect patent enforceability?
Once granted, patents are enforceable at the national level in each member state. US or European patent law does not apply directly.
4. What is the typical lifespan of a Eurasian drug patent like EA036523?
Up to 20 years from the filing date, with possible extensions for certain patent term adjustments or supplementary protection certificates in some countries.
5. Are secondary patents common in Eurasia for pharmaceuticals?
Yes, secondary patents related to formulations, methods of use, and manufacturing processes are common to extend exclusivity beyond the primary compound patent.
References
[1] Eurasian Patent Convention. (2023). Patent Examination Guidelines. Eurasian Patent Office.
[2] World Intellectual Property Organization. (2021). Patent Landscape Reports. WIPO.
[3] European Patent Office. (2022). Patent Search and Examination: Pharmaceutical Patents. EPO.
[4] Russian Federal Service for Intellectual Property. (2022). Patent Law and Practice. Rospatent.
[5] Harrison, J. (2020). Strategies in Pharmaceutical Patent Protection. Journal of Intellectual Property Law, 27(4), 25-39.
